<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05790681</url>
  </required_header>
  <id_info>
    <org_study_id>NN1436-4888</org_study_id>
    <secondary_id>U1111-1271-9231</secondary_id>
    <nct_id>NCT05790681</nct_id>
  </id_info>
  <brief_title>A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers</brief_title>
  <official_title>A Study Investigating the Pharmacokinetic Properties of Insulin Icodec in Children and Adolescents With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin icodec is a new medicine which is under development for use in humans and is not yet&#xD;
      available at the pharmacy. It is being developed for the treatment of diabetes, a condition&#xD;
      that causes high blood sugar levels. Insulin icodec will be investigated in participants with&#xD;
      type 2 diabetes. Participant will get one dose of insulin icodec, which will be administered&#xD;
      in the afternoon or evening of the day of dosing. The study will last for about 8 weeks.&#xD;
      Insulin icodec will be injected into a skin fold with a small needle (subcutaneous&#xD;
      application) using a pen injector prefilled with a volume of 3 milliliter (mL) (a little less&#xD;
      than a quarter of a teaspoonful). The amount of insulin icodec participant will receive&#xD;
      depends on participant's body weight. Participant must not participate if participant meets&#xD;
      certain conditions called exclusion criteria, such as an age of above 18 years when the&#xD;
      informed consent is signed or has serious health conditions. Female participant cannot take&#xD;
      part if she is pregnant, breast-feeding or planning to become pregnant during the study&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2023</start_date>
  <completion_date type="Anticipated">January 21, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 21, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum insulin icodec concentration-time curve after a single dose (AUCIco,0-inf,SD)</measure>
    <time_frame>From 0 hours until infinity after trial product administration (day 1)</time_frame>
    <description>Measured in picomoles*hours per liter (pmol*h/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum insulin icodec concentration after a single dose (Cmax,Ico,SD)</measure>
    <time_frame>From 0 hours until last measurement time after trial product administration (day 1)</time_frame>
    <description>Measured in picomoles per liter (pmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed serum insulin icodec concentration after a single dose (tmax,Ico,SD)</measure>
    <time_frame>From 0 hours until last measurement time after trial product administration (day 1)</time_frame>
    <description>Measured in hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Model-based maximum serum insulin icodec concentration during one dosing interval at steady state (Cmax,Ico,SS,model)</measure>
    <time_frame>From 0 to 168 hours after trial product administration</time_frame>
    <description>Measured in pmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model-based area under the serum insulin icodec concentration-time curve during one dosing interval at steady state (AUC,Ico,Ï„,SS,model)</measure>
    <time_frame>From 0 to 168 hours after trial product administration</time_frame>
    <description>Measured in pmol*h/L.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Participants with Type 2 Diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single subcutaneous (s.c.) fixed dose of insulin icodec (700 units per milliliter [U/mL]) that is 5.6 units per kilogram (U/kg) bodyweight. Subjects will be followed up for 5 weeks after dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin icodec</intervention_name>
    <description>Participants will receive subcutaneously fixed dose of insulin icodec (700 U/mL) that is 5.6 U/kg bodyweight.</description>
    <arm_group_label>Participants with Type 2 Diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Aged 10 to less than (&lt;) 18 years at the time of signing informed consent&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes mellitus greater than or equal to (&gt;=) 30 days prior to&#xD;
             the day of screening&#xD;
&#xD;
          -  Glycated haemoglobin (HbA1c) less than or equal to (&lt;=) 10% (86 millimoles per mole&#xD;
             [mmol/mol]) at screening&#xD;
&#xD;
          -  Treated with basal insulin, premix insulin or continuous subcutaneous insulin infusion&#xD;
             (CSII) with or without bolus insulin or additional anti-diabetic drug(s).&#xD;
&#xD;
          -  Current daily basal insulin treatment &gt;= 0.2 (I) units per kilogram per day (U/kg/day)&#xD;
             with stable doses &gt;=30 days prior to the day of screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to study interventions or related products&#xD;
&#xD;
          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of&#xD;
             childbearing potential and not using adequate contraceptive method&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency dept. 2834</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>April 13, 2023</last_update_submitted>
  <last_update_submitted_qc>April 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on NovoNordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

